14th GAVI BOARD MEETING
Abuja, Nigeria, 4-5 December 2004
SUMMARY REPORT

>>Back to the 14th GAVI Board Meeting

5 Recommendations of the Hib task force

• Board members expressed satisfaction with the thorough and consultative work of the group. Other board members, however, were disappointed that the information was not more conclusive.
• Defined in basic terms, a ‘probe’ study consists of introducing a new vaccine in certain communities and not in others, and tracking disease burden in all communities to see whether, and how much, impact the vaccine has had. Considering that India is home to 20% of the world’s pneumonia disease burden, conducting a Hib probe study in India will be important.

  DECISIONS
  The Board:

  5.1 Approved an overall envelope of $37 million to be awarded through a competitive tender either to a single partner or to a consortium of GAVI partners working together over a four-year period to provide programmatic support to those countries wishing to continue to use Hib vaccine and to those countries wishing to explore whether the introduction of Hib vaccine is a priority for their immunization program/health system.

  5.2 Agreed to appoint an independent review group to review proposals and make a recommendation to the GAVI Board.

  5.3 Requested the Hib task force to develop a more specific process for the solicitation and review of proposals, including proposing the composition of the independent review group.

  5.4 Agreed that the ADIP Management Committee, (with a revised membership to address the broadened mandate), should provide management oversight for the Hib work.

>>Back to the 14th GAVI Board Meeting